Co-promotion agreement with Merck Serono

RNS Number : 0157T

Hutchison China Meditech Limited

01 October 2014

 



Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Press Release

Chi-Med and Merck Serono sign co-promotion agreement

London: Wednesday, 1 October 2014:  Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"), has signed a co-promotion agreement with Merck Serono Co., Ltd. ("Merck Serono") a subsidiary of Merck in China to market certain cardiovascular prescription drug products in China.

Hutchison Sinopharm will exclusively co-promote Merck Serono's Bisoprolol Fumarate tablets, under the Concor® trademark, in several provinces in China. Concor® is a major brand in the beta-blocker sub-segment of the cardiovascular prescription drug market in China.

Chi-Med today operates a commercial network in China of approximately 1,600 cardiovascular market focused medical sales representatives, covering more than 13,000 hospitals, through its joint ventures, Shanghai Hutchison Pharmaceuticals Limited and Hutchison Sinopharm.

Ends

Enquiries

Chi-Med     Christian Hogg, CEO	Telephone:      [phone]
Panmure Gordon (UK) Limited     Richard Gray     Andrew Potts	Telephone:      [phone]
Citigate Dewe Rogerson     Anthony Carlisle     David Dible	Telephone:      [phone] Mobile:             [phone] Mobile:             [phone]

 

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

About Merck Serono China

 
With over 1,300 employees and a nationwide presence, Merck Serono is dedicated to serving the Chinese market. Merck Serono currently markets 15 products in 8 therapeutic areas in China. Merck Serono China is No.1 in fertility and thyroid therapeutic areas, and has strong presence in cardiovascular, endocrinology, oncology and NDD diseases.

 

END

 

 

NRALMMBTMBMJBMI